Transgene: Invest Securities confirms its opinion

(CercleFinance.com) - The analyst firm has reiterated its buy opinion on the stock, with a target price of E2.
6.

The company published its net income for the 1st half, which was stable and in line with analyst expectations.

Cash flow confirms the company's financial horizon of end 2025, including the full amount of the current account advance granted by its main shareholder, a subsidiary of Institut Mérieux", says Invest Securities.

On the operational front, several catalysts are expected in the 4th quarter of 2024, which we believe should encourage renewed interest in the share, which has posted a YTD performance of around -25% to date", adds the research firm.

We foresee a possible recovery in the share price, and an end-of-year rally back to levels closer to those seen at the start of the year. Although relatively early-stage, the current programs have a lot of potential and are positioned on differentiating approaches from a therapeutic strategy point of view'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.